Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,108 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Defects, Congenital Clear all
Active, not recruiting Phase 3 Interventional

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325
View directory record Official record
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Active, not recruiting No phase listed Observational

Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes

NCT03782610
View directory record Official record
Conditions
Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia, Neurodevelopmental Abnormality
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 72 Hours
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Withdrawn No phase listed Observational

Analysis of Cerebral Perfusion Using Head Ultrasound and Multisource Detector Near Infrared Spectroscopy (NIRS) Imaging

NCT01082536
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 2 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting Not applicable Interventional

REHAB Fontan Failure: A Trial of Cardiac Rehabilitation

NCT06150950
View directory record Official record
Conditions
Heart Failure Congenital, Single-ventricle
Interventions
Cardiac rehabilitation, Usual care
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Stanford, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Not listed Not applicable Interventional

Does Patent Foramen Ovale Closure Improve Exercise Capacity & Prevent Blood Flow Through Intrapulmonary Shunt

NCT03904290
View directory record Official record
Conditions
Patent Foramen Ovale
Interventions
PFO Closure
Other
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy

NCT02815540
View directory record Official record
Conditions
Lennox-Gastaut Syndrome, Dravet Syndrome
Interventions
12-Lead ECG, Cannabidiol
Procedure · Drug
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
2 Years to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV

NCT00676689
View directory record Official record
Conditions
Pulmonary Valve Insufficiency, Pulmonary Regurgitation, Dysfunctional RVOT Conduit, Pulmonary Obstruction, Pulmonary Stenosis
Interventions
SAPIEN Transcatheter Valve Implantation
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 2 Interventional

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

NCT00041574
View directory record Official record
Conditions
Pulmonary Hypertension, Lung Disease, Sickle Cell Disease, Cardiac Transplant, Lung Transplant
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

NCT00406926
View directory record Official record
Conditions
Turner Syndrome
Interventions
Somatropin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
9 Months to 4 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2006 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

Multi-site Near Infrared Spectroscopy (NIRS) Monitoring of Children During Exercise

NCT00556231
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
6 Years to 20 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 11, 2026, 10:25 PM EDT
Not yet recruiting No phase listed Observational

Occlutech AFR Fontan Study

NCT07532369
View directory record Official record
Conditions
Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly
Interventions
Occlutech Atrial Flow Regulator Retrospective Data Collection
Device
Lead sponsor
Occlutech International AB
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Phase 1 Interventional

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

NCT03114319
View directory record Official record
Conditions
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma
Interventions
TNO155, TNO155 in combination with EGF816 (nazartinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated Not applicable Interventional

Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage

NCT00665769
View directory record Official record
Conditions
Intraventricular Hemorrhage, Autoregulation
Interventions
Hypercapnia, Normocapnia
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Minute to 7 Days
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

NCT06034405
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Cardiac Amyloidosis, ATTR Amyloidosis Wild Type, ATTR Gene Mutation, ATTRV122I Amyloidosis, Cardiomyopathy, Hypertrophic
Interventions
Tc99-PYP or Tc99-HDMP Scan
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
1,663 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
6
States / cities
Beverly Hills, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Blood Flow Regulation in Individuals With Down Syndrome - Training Study

NCT04854122
View directory record Official record
Conditions
Down Syndrome
Interventions
Combined exercise intervention, Usual care / Sham intervention
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review

NCT01515631
View directory record Official record
Conditions
Alagille Syndrome
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

NCT03153137
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Macitentan 10 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 11, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Probiotics in Infants With Cyanotic Congenital Heart Disease

NCT01018472
View directory record Official record
Conditions
Cyanotic Congenital Heart Disease
Interventions
Bifidobacterium infantis, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 4 Months
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 11, 2026, 10:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 11, 2026, 10:25 PM EDT
Completed No phase listed Observational

Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease

NCT01126372
View directory record Official record
Conditions
Congenital Heart Disease, Prematurity, Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 1 Month
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 11, 2026, 10:25 PM EDT
Withdrawn Not applicable Interventional

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

NCT01980979
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Remodulin
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Sep 11, 2026, 10:25 PM EDT
Approved For Marketing No phase listed Expanded access

A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

NCT04530994
View directory record Official record
Conditions
Alagille Syndrome
Interventions
maralixibat
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Months and older
U.S. locations
14
States / cities
Los Angeles, California • Redwood City, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 11, 2026, 10:25 PM EDT
Terminated No phase listed Observational

NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy

NCT00293137
View directory record Official record
Conditions
Chronic Systolic Heart Failure (Dilated Cardiomyopathy)
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Sep 11, 2026, 10:25 PM EDT
Not listed No phase listed Observational

Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation

NCT02995577
View directory record Official record
Conditions
Single Ventricle Physiology
Interventions
Feeding tolerant, Feeding intolerant, Necrotizing enterocolitis
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 3 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 11, 2026, 10:25 PM EDT